Vir Biotechnology’s sidelined hepatitis B candidate, designed to serve as a “functional cure,” has failed to achieve the ...

There's a vaccine for hepatitis B that, according to the CDC, can help to prevent millions of deaths worldwide.

Functional cure, defined as durable hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA titers below the lower limit of detection (LLOD), is associated with better clinical outcomes of ...

Q1 2025 Earnings Call Transcript May 6, 2025 Dynavax Technologies Corporation misses on earnings expectations. Reported EPS is $0.01 EPS, expectations were $0.03. Operator: Good day ladies and ...

Chronic hepatitis B infection is primarily driven by persistence of HBV cccDNA and integration of HBV DNA into the human genome in liver cells, the primary source of hepatitis B surface antigen ...

Functional cure of chronic hepatitis B (CHB) remains a major clinical challenge. Current therapies—including nucleos(t)ide ...

Richard Lepke; Senior Director, Investor Relations; Vir Biotechnology Inc. Marianne De Backer; Chief Executive Officer, Director; Vir Biotechnology Inc. Mark Eisner; ...

Interim results from the phase 2b B-Clear showed that bepirovirsen reduced levels of hepatitis B surface antigen (HBsAg ... are available – such as Gilead's polymerase inhibitor Viread ...

Hepatitis B affects almost 300 million people worldwide, according to GSK, and while nucleoside/nucleotide analogue (NA) drugs to treat it are available – such as Gilead’s polymerase inhibitor ...